Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611000547943
Ethics application status
Approved
Date submitted
20/05/2011
Date registered
30/05/2011
Date last updated
5/09/2019
Date data sharing statement initially provided
5/09/2019
Date results information initially provided
5/09/2019
Type of registration
Retrospectively registered

Titles & IDs
Public title
PRINCess: The Prediction of Regression in CIN2 - The Conservative Management of Cervical Intraepithelial Neoplasia (CIN) 2 in Young Women
Scientific title
PRINCess: The Prediction of Regression in CIN2 - A prospective study of young women under the age of 25 with biopsy proven CIN2 undergoing conservative management with assessment of regression, stable disease and progression.
Secondary ID [1] 284794 0
Nil Known
Universal Trial Number (UTN)
U1111-1116-3209
Trial acronym
PRINCess
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cervical Intraepithelial Neoplasia (CIN) 2 257833 0
Condition category
Condition code
Cancer 258002 258002 0 0
Cervical (cervix)

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Conservative Management for Cervical Intraepithelial Neoplasia (CIN) 2 for 24 months i.e. six monthly colposcopy and cervical biopsy for a total of two years
Intervention code [1] 256895 0
Not applicable
Comparator / control treatment
No treatment
Control group
Uncontrolled

Outcomes
Primary outcome [1] 258862 0
Progression rates of CIN 2 in women under the age of 25. Progression will be detected at colposcopy in conjunction with smear and biopsy.
Timepoint [1] 258862 0
24 months
Primary outcome [2] 258863 0
Regression rates of CIN 2 in women under the age of 25.
Regression will be detected at colposcopy in conjunction with smear and biopsy.
Timepoint [2] 258863 0
24 months
Primary outcome [3] 258926 0
To identify the safety of follow-up, as opposed to surgical management, of CIN 2, in young women under the age of 25.
The outcome is either progression, regression or no change after 2 years - all assessed by colposcopy, smear and biopsy.
Timepoint [3] 258926 0
24 months
Secondary outcome [1] 264988 0
The correlation of CIN 2 with immunohistochemical parameters: P16, Proex, Ki67, HPV typing will be assessed.
Timepoint [1] 264988 0
24 months
Secondary outcome [2] 265097 0
Compliance with follow-up will also be assessed as an outcome measure.
Compliance will be assessed by attendance at clinic, routine prompts to clinic will be allowed.
Timepoint [2] 265097 0
24 months

Eligibility
Key inclusion criteria
All women up to the age of 25 attending colposcopy clinics with biopsy proven CIN 2 with the entire lesion accessible at colposcopy. Participants in this study must agree to six monthly colposcopy and cervical biopsy for a total of two years.
Minimum age
15 Years
Maximum age
25 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria include those women with higher grade cervical intraepithelial neoplasia and findings suspicions for invasion on colposcopic assessment. Adenocarcinoma-in-situ is an exclusion category as is incomplete colposcopy.

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Defined population
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
30/04/2010
Actual
14/04/2010
Date of last participant enrolment
Anticipated
Actual
19/10/2016
Date of last data collection
Anticipated
31/10/2018
Actual
28/03/2019
Sample size
Target
600
Accrual to date
Final
616
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 8555 0
The Royal Women's Hospital - Parkville
Recruitment hospital [2] 8556 0
The Chris O’Brien Lifehouse - Camperdown
Recruitment postcode(s) [1] 16659 0
3052 - Parkville
Recruitment postcode(s) [2] 16660 0
2050 - Camperdown
Recruitment outside Australia
Country [1] 2791 0
New Zealand
State/province [1] 2791 0
Christchurch

Funding & Sponsors
Funding source category [1] 257352 0
University
Name [1] 257352 0
University of Otago - Christchurch
Country [1] 257352 0
New Zealand
Funding source category [2] 257353 0
Hospital
Name [2] 257353 0
Canterbury District Health Board
Country [2] 257353 0
New Zealand
Funding source category [3] 267141 0
Charities/Societies/Foundations
Name [3] 267141 0
Cancer Society of New Zealand, Canterbury West Coast Division
Country [3] 267141 0
New Zealand
Funding source category [4] 289410 0
Government body
Name [4] 289410 0
Health Research Council NZ
Country [4] 289410 0
New Zealand
Primary sponsor type
University
Name
University of Otago - Christchurch
Address
Private Bag 4711
Christchurch 8140
Country
New Zealand
Secondary sponsor category [1] 256594 0
Hospital
Name [1] 256594 0
Canterbury District Health Board
Address [1] 256594 0
Private Bag 4710
Christchurch 8140
Country [1] 256594 0
New Zealand

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 259374 0
Multiregion Ethics Committee - New Zealand
Ethics committee address [1] 259374 0
PO Box 5013
Wellington
Ethics committee country [1] 259374 0
New Zealand
Date submitted for ethics approval [1] 259374 0
Approval date [1] 259374 0
14/04/2010
Ethics approval number [1] 259374 0
MEC/09/07/079
Ethics committee name [2] 291171 0
Ethics Review Committe (RPAH Zone)
Ethics committee address [2] 291171 0
Research Development office
Royal Prince Alfred Hospital
Camperdown NSW 2050
Ethics committee country [2] 291171 0
Australia
Date submitted for ethics approval [2] 291171 0
Approval date [2] 291171 0
14/11/2013
Ethics approval number [2] 291171 0
13/RPAH/352

Summary
Brief summary
Cervical intraepithelial neoplasia 1, 2 or 3 is the term used to describe a range of cellular changes on the cervix that over time can regress to normal or progress to cervical cancer. Cervical cancers are usually preceded by a long phase of preinvasive disease. Evidence has shown that there is a 43% likelihood of regression of CIN 2, a 35% likelihood of persistence of CIN 2 and a 20% probability of progression to CIN 3. Evidence in adolescents has shown an even higher rate of regression. The current treatment for this abnormality is a LLETZ biopsy of the cervix. This treatment is associated with complications in future pregnancies – premature rupture of membranes and preterm labour. Because of the high regression rate and pregnancy complications, young women, up to age 25, with biopsy proven CIN 2 at Christchurch and Dunedin Hospitals will be offered inclusion in the study. This will involve 6 monthly colposcopy clinic visits where a cervical smear, biopsy and tests for HPV, Proex, P16, Ki67 as opposed to immediate surgical management. If there is progression of this change to CIN 3 throughout follow-up a LLETZ will be offered. Follow-up is for 24 months – if the CIN 2 abnormality persists, LLETZ will be offered.
Trial website
Trial related presentations / publications
Public notes
The trial has recruited women in many New Zealand hospitals.

Contacts
Principal investigator
Name 31445 0
A/Prof Peter H Sykes
Address 31445 0
University of Otago - Christchurch
Department of O & G
Private Bag 4711
Christchurch 8140
Country 31445 0
New Zealand
Phone 31445 0
+64 3 364 4630
Fax 31445 0
+64 3 364 4634
Email 31445 0
[email protected]
Contact person for public queries
Name 14692 0
Ms Ms Dianne Harker
Address 14692 0
Private Bag 4711
Christchurch
Country 14692 0
New Zealand
Phone 14692 0
+64 3 3644624
Fax 14692 0
+64 3 3644634
Email 14692 0
[email protected]
Contact person for scientific queries
Name 5620 0
A/Prof Associate Professor Peter Sykes
Address 5620 0
Christchurch Women’s Hospital
Private Bag 4710
Christchurch
Country 5620 0
New Zealand
Phone 5620 0
+64 3 3644630
Fax 5620 0
+64 3 3644634
Email 5620 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
IPD sharing not planned.


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
3202Study protocol  [email protected]
3203Informed consent form  [email protected]



Results publications and other study-related documents

Documents added manually
Current Study Results
Update to Study Results
Doc. No.TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
494Conference abstractNo Simcock B, Sykes P, Innes C, Harker D, Williman J,... [More Details]
495Conference abstractNo Sykes P, Innes C, Harker D, Whitehead M, Van der G... [More Details]
496Conference abstractNo Simcock B, Innes C, van der Griend R, Williman J, ... [More Details]
497Conference abstractNo Dempster-Rivett K, Innes CRH, Simcock B, Sykes PH ... [More Details]
498Conference abstractNo Sykes PH, Innes CRH, van der Griend RA, Fitzgerald... [More Details]
599Study results articleYes Innes CRH, Sykes PH, Harker D, Williman JA, Van de... [More Details]
600Study results articleYes Sykes P, Innes C, Harker D, Whitehead M, van der G... [More Details]
2386Basic resultsNo 335767-(Uploaded-30-08-2019-09-05-43)-Basic results summary.docx
3067Plain language summaryNo Background: Women with cervical intraepithelial ne... [More Details]

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseObservational Management of CIN 2 in Young Women: A Prospective Multicenter Trial.2016https://dx.doi.org/10.1097/LGT.0000000000000244
EmbaseChanges in human papillomavirus genotypes associated with cervical intraepithelial neoplasia grade 2 lesions in a cohort of young women (2013-2016).2018https://dx.doi.org/10.1016/j.pvr.2018.10.010
EmbaseBlimp-1 is a prognostic indicator for progression of cervical intraepithelial neoplasia grade 2.2022https://dx.doi.org/10.1007/s00432-022-03993-4
N.B. These documents automatically identified may not have been verified by the study sponsor.